76 related articles for article (PubMed ID: 36052772)
1. Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer.
Lu S; Fang J; Wang Z; Fan Y; Liu Y; He J; Zhou J; Hu J; Xia J; Liu W; Shi J; Yi J; Cao L
Cancer Med; 2023 Feb; 12(3):2666-2676. PubMed ID: 36052772
[TBL] [Abstract][Full Text] [Related]
2. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Lu S; Wu L; Jian H; Cheng Y; Wang Q; Fang J; Wang Z; Hu Y; Han L; Sun M; Miao L; Ding C; Cui J; Wang K; Li B; Li X; Ye F; Liu A; Pan Y; Cang S; Zhou H; Sun X; Shen Y; Wang S; Zhang W; He Y
Lancet Respir Med; 2023 Jul; 11(7):624-636. PubMed ID: 37156249
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Shiraishi Y; Kishimoto J; Sugawara S; Mizutani H; Daga H; Azuma K; Matsumoto H; Hataji O; Nishino K; Mori M; Shukuya T; Saito H; Tachihara M; Hayashi H; Tsuya A; Wakuda K; Yanagitani N; Sakamoto T; Miura S; Hata A; Okada M; Kozuki T; Sato Y; Harada T; Takayama K; Yamamoto N; Nakagawa K; Okamoto I
JAMA Oncol; 2024 Mar; 10(3):315-324. PubMed ID: 38127362
[TBL] [Abstract][Full Text] [Related]
4. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With
Park S; Kim TM; Han JY; Lee GW; Shim BY; Lee YG; Kim SW; Kim IH; Lee S; Kim YJ; Park JH; Park SG; Lee KH; Kang EJ; Kim JW; Shin SH; Ock CY; Nam BH; Lee J; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
J Clin Oncol; 2024 Apr; 42(11):1241-1251. PubMed ID: 37861993
[TBL] [Abstract][Full Text] [Related]
5. Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked.
Bodor JN; Patel JD; Wakelee HA; Levy BP; Borghaei H; Pellini B; Costello MR; Dowell JE; Finley G; Huang CH; Neal JW; Nieva JJ; Puri S; Socinski MA; Thomas C; Ross EA; Litwin S; Clapper ML; Treat J
Clin Lung Cancer; 2023 Nov; 24(7):e242-e246. PubMed ID: 37451930
[TBL] [Abstract][Full Text] [Related]
6. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.
Felip E; Altorki N; Zhou C; Vallières E; Martínez-Martí A; Rittmeyer A; Chella A; Reck M; Goloborodko O; Huang M; Belleli R; McNally V; Srivastava MK; Bennett E; Gitlitz BJ; Wakelee HA
Ann Oncol; 2023 Oct; 34(10):907-919. PubMed ID: 37467930
[TBL] [Abstract][Full Text] [Related]
7. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).
Nadal E; Rodríguez-Abreu D; Simó M; Massutí B; Juan O; Huidobro G; López R; De Castro J; Estival A; Mosquera J; Sullivan I; Felip E; Blasco A; Guirado M; Pereira E; Vilariño N; Navarro V; Bruna J
J Clin Oncol; 2023 Oct; 41(28):4478-4485. PubMed ID: 37603816
[TBL] [Abstract][Full Text] [Related]
8. Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.
Zhou C; Wang Z; Sun M; Cao L; Ma Z; Wu R; Yu Y; Yao W; Sun S; Chen J; Zhuang W; Cui J; Chen X; Lu Y; Shen H; Hu C; Liu J; Liu Y; Wang M; Li X; Sun P; Shu Y; Zhou J; Li J; Gu K; Wang C; Zhao H; Zhang Y; Liu C; Wang J; Chen R; Qin M; Wang H; Yang J
Nat Cancer; 2023 Jun; 4(6):860-871. PubMed ID: 37322367
[TBL] [Abstract][Full Text] [Related]
9. Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.
Grande E; Bamias A; Galsky MD; Kikuchi E; Davis ID; Arranz JÁ; Rezazadeh Kalebasty A; Garcia Del Muro X; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Puente J; Li JR; Bernhard S; Nicholas A; Telliez J; De Santis M
Eur Urol Open Sci; 2023 Dec; 58():28-36. PubMed ID: 37954037
[TBL] [Abstract][Full Text] [Related]
10. SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
Rudin CM; Liu SV; Soo RA; Lu S; Hong MH; Lee JS; Bryl M; Dumoulin DW; Rittmeyer A; Chiu CH; Ozyilkan O; Johnson M; Navarro A; Novello S; Ozawa Y; Tam SH; Patil NS; Wen X; Huang M; Hoang T; Meng R; Reck M
J Clin Oncol; 2024 Jan; 42(3):324-335. PubMed ID: 37976444
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC.
Mathieu LN; Larkins E; Sinha AK; Mishra-Kalyani PS; Jafri S; Kalavar S; Ghosh S; Goldberg KB; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2023 Aug; 29(16):2973-2978. PubMed ID: 36951523
[TBL] [Abstract][Full Text] [Related]
12. Response- and Progression-Based End Points in Trial and Observational Cohorts of Patients With NSCLC.
Lu Y; Langerman SS; McCain E; Magee K; Maund SL; Srivastava MK; Samant M
JAMA Netw Open; 2024 May; 7(5):e249286. PubMed ID: 38700864
[TBL] [Abstract][Full Text] [Related]
13. Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial.
Lim SM; Peters S; Ortega Granados AL; Pinto GDJ; Fuentes CS; Lo Russo G; Schenker M; Ahn JS; Reck M; Szijgyarto Z; Huseinovic N; Zografos E; Buss E; Stjepanovic N; O'Donnell S; de Marinis F
Nat Commun; 2023 Nov; 14(1):7301. PubMed ID: 37951954
[TBL] [Abstract][Full Text] [Related]
14. Use of Novel National Data Sets to Monitor Chemotherapy Use and Outcomes: A Retrospective Cohort Study of Non-Small-Cell Lung Cancer in Aotearoa New Zealand.
Minhinnick AM; Dunn AH; Arabnejad V; Paddison JS; Jackson CGCA; Pointer SM; Gurney JK; Cameron LB
JCO Oncol Pract; 2024 Mar; 20(3):401-408. PubMed ID: 38206292
[TBL] [Abstract][Full Text] [Related]
15. IMpower210: A phase III study of second-line atezolizumab
Wu YL; Lu S; Chen G; He J; Feng J; Zhang Y; Jiang L; Pan H; Chang J; Fang J; Cai A; Bu L; Shi J; Xia J
Chin J Cancer Res; 2024 Apr; 36(2):103-113. PubMed ID: 38751442
[TBL] [Abstract][Full Text] [Related]
16. C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
Patil NS; Zou W; Mocci S; Sandler A; Ballinger M; Flynn S; Kowanetz M; Hegde PS
PLoS One; 2021; 16(2):e0246486. PubMed ID: 33534859
[TBL] [Abstract][Full Text] [Related]
17. Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study).
Amari L; Tomasini P; Dantony E; Rousseau-Bussac G; Ricordel C; Bigay-Game L; Arpin D; Morel H; Veillon R; Justeau G; Huchot E; Fournel P; Vergnenegre A; Bizeux A; Subtil F; Clarisse B; Decroisette C; Chouaid C; Greillier L; Bylicki O
Lung Cancer; 2024 May; 193():107843. PubMed ID: 38830303
[TBL] [Abstract][Full Text] [Related]
18. Effect of AGEs-RAGE system on the efficacy of PD-1 inhibitors in the treatment of driver-gene mutation negative advanced non-squamous non-small cell lung cancer.
Li X; Wang G; Sun X; Feng Y; Wang L; Sun G; Qiao H
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):155-160. PubMed ID: 38279452
[TBL] [Abstract][Full Text] [Related]
19. The Addition of Atezolizumab to Chemotherapy in Non-Small Cell Lung Cancer: A Trial-Based Review and Meta-Analysis.
Fitri NK; Nainggolan BWM; Firsty NN; Pradana A; Sari DK
World J Oncol; 2024 Feb; 15(1):72-80. PubMed ID: 38274722
[TBL] [Abstract][Full Text] [Related]
20. Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience.
Faber MG; Wang C; Kommi Reddy S; Meagher A; Early A; Chen H; Dy GK
Lung Cancer; 2022 Mar; 165():49-53. PubMed ID: 35085984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
